Hudson Bay Capital Management LP Assembly Biosciences, Inc. Transaction History

Hudson Bay Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.87 - $1.13 $545,025 - $707,906	-626,466 Reduced 75.82%	199,789 $177,000
Q2 2023 Aug 14, 2023	SELL	$0.81 - $1.15 $100,233 - $142,306	-123,745 Reduced 13.03%	826,255 $950,000
Q1 2023 May 15, 2023	SELL	$0.8 - $1.74 $60,000 - $130,500	-75,000 Reduced 7.32%	950,000 $798,000
Q4 2022 Feb 14, 2023	SELL	$1.09 - $20.4 $54,500 - $1.02 Million	-50,000 Reduced 4.65%	1,025,000 $1.33 Million
Q4 2021 Feb 14, 2022	BUY	$2.13 - $3.46 $479,250 - $778,500	225,000 Added 26.47%	1,075,000 $2.51 Million
Q3 2021 Nov 15, 2021	BUY	$3.14 - $3.9 $314,000 - $390,000	100,000 Added 13.33%	850,000 $2.96 Million
Q2 2021 Aug 16, 2021	BUY	$3.8 - $4.56 $494,000 - $592,800	130,000 Added 20.97%	750,000 $2.91 Million
Q1 2021 May 14, 2021	BUY	$4.33 - $6.63 $476,733 - $729,963	110,100 Added 21.59%	620,000 $2.85 Million
Q4 2020 Feb 12, 2021	BUY	$4.87 - $17.29 $2.48 Million - $8.82 Million	509,900 New	509,900 $3.09 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $714M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.